Trunome, developed by Acrannolife Genomics, offers a non-invasive blood test for early disease detection in post-transplant patients
This innovative technology is the first of its kind in Asia and has been developed entirely in India, protected by US patents
Trunome's cost is around $500 in India, significantly lower than competitors, whose tests cost about ₹2.5 lakhs
The company has tested over 5,000 samples and positively impacted more than 1,500 lives in their patient care initiatives
Trunome has contracts with six hospitals in India and is partnering with five major transplant hospitals across the country
For FY21-22, Trunome reported revenue of ₹5 Crores and aims to exceed ₹10 Crores for FY22-23, with a monthly run rate of ₹35 Lakhs
During their Shark Tank pitch, they received a joint offer of ₹1.5 Crores for 2% of the company, which the founders accepted
Despite skepticism from some sharks regarding market size, Trunome is expected to achieve revenues of ₹4,000 Crores in the future